Merck’s potential for upside hinges on its ability to execute on several key fronts: successfully advancing its pipeline, expanding geographically, and making strategic acquisitions.

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here.

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff.

(Reuters) -Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

Merck KGaA, the German science and technology group, trimmed its profit forecast, citing a weakening US dollar and uncertainty around global tariffs. The stock tumbled.

U.S. biopharmaceutical giant Merck announced the start of construction for a $1-billion, 470,000-sq-ft biologics center of excellence in Wilmington, Del. Officially called Merck Wilmington Biotech ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.